SUBSCRIBE
SUBSCRIBE

Phase II

Policy
Biopharma Update on the Novel Coronavirus: May 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
May 5, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
May 4, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biotech Professionals Express Fears…and Hope, During Pandemic
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
May 1, 2020
 · 
5 min read
 · 
Gail Dutton
Bio NC
Clinical Catch-Up: April 27-May 1
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
May 1, 2020
 · 
11 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
May 1, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
April 30, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
April 29, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
April 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Jenner Institute’s COVID-19 Vaccine Expected to Be Tested in 6,000 People Starting in May
With emergency approval, the Oxford University researchers believe they could have a few million doses of the vaccine available by September if it is proven effective.
April 28, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Axsome’s Drug for Agitation in Alzheimer’s Hits Primary Endpoints in Phase II/III Trial
About 70% of AD patients have symptoms of agitation, which is marked by emotional distress, aggressive behaviors, disruptive irritability and loss of inhibition.
April 27, 2020
 · 
3 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
February 7, 2024
 · 
4 min read
Drug Development
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
February 7, 2024
 · 
9 min read
Drug Development
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
February 7, 2024
 · 
16 min read
Drug Development
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
February 7, 2024
 · 
10 min read
Drug Development
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize
February 7, 2024
 · 
6 min read
Drug Development
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
February 7, 2024
 · 
6 min read
Drug Development
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
February 7, 2024
 · 
7 min read
Drug Development
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
February 7, 2024
 · 
9 min read
Drug Development
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
February 6, 2024
 · 
7 min read
Drug Development
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
February 6, 2024
 · 
9 min read
Drug Development
MiNK Therapeutics’ AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
February 6, 2024
 · 
4 min read
Drug Development
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
February 6, 2024
 · 
6 min read
Drug Development
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
February 6, 2024
 · 
3 min read
Drug Development
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
February 6, 2024
 · 
9 min read
Drug Development
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
February 5, 2024
 · 
12 min read
Drug Development
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
February 5, 2024
 · 
7 min read
Drug Development
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
February 5, 2024
 · 
10 min read
Drug Development
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
February 5, 2024
 · 
2 min read
Drug Development
ProfoundBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of PRO1107, a Protein Tyrosine Kinase 7 (PTK7)-Targeted Antibody-Drug Conjugate Incorporating a Novel, Proprietary Hydrophilic MMAE-Based Linker-Drug
February 5, 2024
 · 
3 min read
Drug Development
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
February 5, 2024
 · 
4 min read
Load More